BIA Separations selected for manufacturing process development support for gene therapy pipeline

22 Jul 2019

The company will provide expertise in next-generation biomolecule purification processes and long-term supply of CIMmultus monolithic columns.

BIA Separations is collaborating with AveXis, a Novartis company, to enhance the commercial purification process for its gene therapy pipeline, beginning with Zolgensma (onasemnogene abeparvovec-xioi), the first FDA-approved gene therapy indicated for the treatment of pediatric patients with spinal muscular atrophy (SMA) who are less than 2 years of age.

BIA Separations selected for manufacturing process development support for gene therapy pipeline

Zolgensma is a one-time infusion that provides a functional copy of the human SMN gene to halt disease progression through sustained SMN protein expression.

BIA was selected as a result of its expertise in viral and DNA purification, particularly adeno-associated virus (AAV), and chromatographic technology for the purification and analysis of biomolecules.

Aleš Štrancar, CEO of BIA Separations commented: “We are proud to have been selected to support AveXis’ gene therapy pipeline. We look forward to seeing how Zolgensma helps the SMA community and the whole BIA team is honored to be a part of this important work.”

Andy Stober, Senior Vice President of Technical Operations for AveXis added: “We are especially grateful that BIA Separations shared, and operated, with the same sense of urgency we did to help bring gene therapy to the SMA community. BIA’s experience with AAV purification and its chromatographic technology were important contributions and we look forward to our continued work together.”

Read More

Related news

CPhI and AAPS partner to expand expert scientific content at CPhI North America

CPhI and AAPS partner to expand expert scientific content at CPhI North America

10 Jan 2020

CPhI and the American Association of Pharmaceutical Scientists (AAPS) today announced a partnership to expand the scientific content of activities sponsored by CPhI, including CPhI North America—the only event to bring the entire North American pharmac...

Read more 
Mylan recalls batches of Nizatidine capsules after nitrosamine detected in API

Mylan recalls batches of Nizatidine capsules after nitrosamine detected in API

9 Jan 2020

The US arm of generic and specialty pharma company Mylan Pharmaceuticals has recalled three lots of its heartburn drug Nizatidine in capsule form amid fears of possible nitrosamine contamination.

Read more 
New HQ for developer of world's first fully automated drug discovery platform

New HQ for developer of world's first fully automated drug discovery platform

8 Jan 2020

End-to-end robotic platform provides biotechnology companies, pharmaceutical corporations and academic centres with cost-effective and reproducible drug discovery data.

Read more 
Catalent completes purchase of biologics fill-finish and oral solid dose facility

Catalent completes purchase of biologics fill-finish and oral solid dose facility

7 Jan 2020

Facility provides European customers with great biologics and oral dose capabilities that can help reduce time-to-market.

Read more 
Boxing clever: Smart packs improving communication with patients

Boxing clever: Smart packs improving communication with patients

6 Jan 2020

Drug industry expectations of packaging are evolving with developers now seeking techs that help patients get more from their medicines.

Read more 
WuXi STA opens large-scale oligonucleotide manufacturing facility

WuXi STA opens large-scale oligonucleotide manufacturing facility

6 Jan 2020

Expands company's capacity and capability for this novel modality, providing a one-stop shop from preclinical to commercial.

Read more 
NIH researchers discover new autoinflammatory disease

NIH researchers discover new autoinflammatory disease

3 Jan 2020

Mutations in the RIPK1 gene responsible for CRIA syndrome.

Read more 
UCB to build new biotech manufacturing plant in Belgium

UCB to build new biotech manufacturing plant in Belgium

31 Dec 2019

Capacity to serve global late-stage development and commercial manufacturing of monoclonal antibody drug substance to support new product launches.

Read more 
BioAscent scientists help identify potential new treatments for cancer

BioAscent scientists help identify potential new treatments for cancer

30 Dec 2019

Collaboration discovers potent and selective inhibitors of enzymes associated with the development of some cancers and neurodegenerative diseases.

Read more 
Astellas strengthens immuno-oncology pipeline with acquisition of Xyphos Biosciences

Astellas strengthens immuno-oncology pipeline with acquisition of Xyphos Biosciences

27 Dec 2019

Acquisition adds talent and proprietary therapeutic platform to accelerate next-generation cancer immunotherapy.

Read more